Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis.

Medicine (Baltimore) · 2020 · PMC7717767 · PMID 33285754

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, lixisenatide in the ELIXA trial [ 5 ] showed a trend for risk increase in MACE and the 2 drug classes in other cardiovascular outcome trials [ 6 – 12 ] showed a trend for risk reduction in MACE in this subgroup, with no statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.